The DDI Advisory Board, which bolsters our strategic direction, consists of internationally recognized experts with proven track records in pharmaceutical drug discovery, development and commercialization.

The board:

  • Holds quarterly and ad hoc meetings as needed
  • Engages and interacts frequently with the DDI team
  • Conducts scientific reviews of proposed and ongoing projects
  • Manages portfolios
  • Offers guidance for business development and licensing

Timothy R. Wright, BS – Chair of Advisory Board


Mr. Wright founded the DDI in 2011. He is currently executive vice president (VP) of Business Development, Strategy and Innovation at Teva Pharmaceuticals. Previously he was president of Covidien Pharmaceuticals, president of Global Operations of Elan Pharmaceuticals, and senior VP (SVP) at DuPont Merck Pharmaceutical.

John Bryd, MD


Dr. Byrd is Distinguished University Professor of Medicine, Director of the Division of Hematology and holds the D. Warren Brown Endowed Chair of Leukemia Research at the at The Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). He is a physician scientist focused on immune and molecular pharmacology and clinically on developing new treatments for acute myeloid leukemia and chronic lymphocytic leukemia. He has more than 400 publications related to his work.

David Carbone, MD, PhD


Dr. Carbone is professor of Internal Medicine, director of the OSUCCC – James Thoracic Oncology Center and the Barbara J. Bonner Chair in Lung Cancer Research. He is a world-renowned lung cancer expert with over 200 peer-reviewed publications.

Pat Confalone, PhD


Dr. Confalone is R&D consultant at Confalone Consulting, LLC. He has over 40 years of R&D experience and is an expert in medicinal and process chemistry. He was previously VP at DuPont USA, VP at Bristol-Myers Squibb and SVP at DuPont Merck Pharmaceuticals.

Arthur Morelli, BA


Mr. Morelli is CEO of Arthur F. Morelli and Associates Consulting. He is a pharmaceutical industry professional with over 30 years of leadership experience as senior director at DuPont Pharma; VP, Elan Biopharmaceuticals; VP, Cardinal Health; EVP, Solstice Neurosciences Inc.; and VP, Covidien/Mallinckrodt Pharmaceuticals.

Herbert Neuman, MD, MBA


Dr. Neuman is president, R3xperts Consulting, a boutique pharmaceutical industry consultancy. He is board certified in Internal Medicine and has over 15 years of experience in the Pharma industry. He was previously VP of global regulatory affairs at Mallinckrodt and chief medical officer and VP medical affairs at Covidien Pharma.

Robert Stein, MD, PhD


Dr. Stein is president, R&D at Agenus Inc. He brings over 30 years of experience in innovation and leadership in the Pharma industry. Previously he was executive vice president (EVP) of research & development for DuPont Merck Pharmaceuticals, president and chief scientific officer (CSO) for Incyte Pharmaceuticals, president of Roche, Palo Alto, and CEO of KineMed.

For more information, contact the DDI at ddi@osumc.edu.

Contact the DDI

Email: ddi@osumc.edu
Phone: 614-685-6957